Certificate in Cancer Immunotherapy

CP2_-_Copy.png

The Society for Immunotherapy of Cancer (SITC) is pleased to offer physicians and qualified healthcare providers the opportunity to earn a Certificate in Cancer Immunotherapy, supporting their knowledge and skills to provide effective and safe care for patients treated with cancer immunotherapy. Learners can expect to develop a comprehensive understanding of cancer immunotherapies, including checkpoint inhibitors, cell therapies and many others, as well as the management of side effects, allowing them to successfully implement immunotherapy in clinical practice.  

The Certificate in Cancer Immunotherapy consists of eight independent learning modules that can be stacked to earn the SITC Graduate in Cancer Immunotherapy (SITC-G) certificate. The SITC-G certificate identifies a healthcare provider as completing specialized training in cancer immunotherapy.  All modules are approved for CME, CNE, CPE and MOC credits, except where noted.

The final assessment for this program is currently under development and an announcement will be sent as soon as it is available. 

Certificate

CP1.png

SITC Graduate in Cancer Immunotherapy / SITC-G




Cost per Module

SITC Member Price: $25.00
Non-Member Price: $31.25



Learner Notification

Learning Modules

  • Module 1: Basic Immunology Concepts, Available now!
    • This course, Module 1: Basic Immunology Concepts, will cover some of the key immunology needed to understand the rest of the certificate program.
  • Module 2: Basic Cancer Immunotherapy Concepts, Available now!
    • This course, Module 2: Basic Cancer Immunotherapy Concepts, will cover the biological foundation of cancer immunotherapy, applying the basic immunology you learned in the last module to help lay the foundation for future topics in this program.
  • Module 3: Immune Checkpoint Blockade, Available now!
    • This course, Module 3: Immune Checkpoint Blockade, will cover the biological foundation of immune checkpoint blockade therapies as well as diving into their clinical use.
    • Module 6: Oncolytic Viruses and Intralesional Therapy, Available now!
      • This course, Module 6: Oncolytic Viruses and Intralesional Therapy, will cover the biological foundation and clinical implementation of intratumoral therapies and oncolytic viruses. 
      • This activity does not offer continuing education credit.
    • Module 7: CAR T Cell and Cellular TherapyAvailable now!
      • This course, Module 7: CAR T Cell and Cellular Therapy, will cover the mechanisms and clinical administration of cellular therapies for cancer, including an emphasis on adverse event management.
    • Module 8: Implementing Cancer Immunotherapy in Clinical Practice, Available now!
      • This course, Module 8: Implementing Cancer Immunotherapy in Clinical Practice, will cover the practical aspects of instituting immunotherapy treatments in a clinical practice, such as education considerations, value-based care, and access to patient and provider resources.

    Target Audiences

    The primary target audience for the program is treating physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate will also be available to practicing, licensed NPs, PAs, and PharmDs (or RPh degree holders involved in direct clinical services), or global equivalent. The courses will be available to those who are not practicing clinicians, but they will not be eligible to earn the certificate.

    Requirements

    The requirements to earn the certificate include:

    • Must be a treating physician (U.S. licensed MD / DO or global equivalent), or a practicing licensed NP, PA, PharmD or RPh degree holder involved in direct clinical services, or global equivalent
    • Complete the coursework (all eight modules)
      • anticipated to be approximately 1 hour each, for a total of 8 hours
    • Pass all end-of-module assessments
    • Successfully complete a comprehensive exam covering all modules

    Certificate Term

    The certificate term is two years. Then, to earn a current certificate, which allows one to continue to use the SITC-G designation, an individual will need to take and pass updated coursework and assessments. If one misses the deadline for reissuance, he or she will need to retake and pass the full program.

    Certificate Program Task Force


    CHAIR

    Robert L. Ferris, MD, PhD
    University of Pittsburgh Medical Center Hillman Cancer Center

    Members

    Leisha Emens, MD, PhD –
    University of Pittsburgh Medical Center Hillman Cancer Center
    Umar Farooq, MD – University of Iowa
    Silvia Formenti, MD – Weill Cornell Medicine
    Sigrun Hallmeyer, MD – Advocate Medical Group
    Howard Kaufman, MD, FACS –
    Ankyra Therapeutics/Massachusetts General Hospital
    Jose Lutzky, MD, FACP – University of Miami Sylvester Cancer Center
    George Weiner, MD – University of Iowa